Oragenics Inc. (AMEX:OGEN) saw an upside of 4.64% to $0.61 after adding $0.03 on Tuesday. The 5-day average trading volume is 1,030,491 shares of the company’s common stock. It has gained $0.6100 in the past week. An average of 1,245,943 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,769,007.
OGEN’s 1-month performance is -14.98% or -$0.0887 on its low of $0.5670 reached on 10/08/21. The company’s shares have touched a 52-week low of $0.38 and high of $1.80, with the stock’s rally to the 52-week high happening on 02/09/21. YTD, OGEN has achieved 29.18% or $0.1445. However, the current price is down -66.28%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Jan 14, 271 days have gone by since the last insider trading activity for Oragenics Inc. (OGEN). Hernandez Joseph (10% Owner) most recently sold 870,854 shares at $0.98 per share on Jan 14. This transaction cost the insider $856,485. 10% Owner, Hernandez Joseph, sold 257,510 shares at a price of $0.80 on Jan 13. Then, on Jan 12, 10% Owner Hernandez Joseph sold 629,707 shares at a price of $0.73 per share. This transaction amounted to $460,190.
Oragenics Inc. (OGEN) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.23 for the sector.OGEN stock has a beta of 0.17. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 2.23.
Oragenics Inc.’s quick ratio for the period ended June 29 was 16.40, with the current ratio over the same period at 16.40 meaning that OGEN stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00. The firm’s gross profit as reported stood at $11000.0 against revenue of $26.64 million.
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Analysts expected OGEN to announce -$0.04 per share in earnings in its latest quarter, but it posted -$0.03, representing a 25.00% surprise. EBITDA for the quarter stood at more than -$3.83 million. OGEN stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 2.51 million, with total debt at $0.58 million. Shareholders hold equity totaling $116.19 million
Let’s look briefly at Oragenics Inc. (OGEN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 39.83% to suggest the stock is trending Neutral, with historical volatility in this time period at 27.81%.
The stock’s 5-day moving average is $0.5847, reflecting a -1.05% or -$0.0063 change from its current price. OGEN is currently trading -8.69% above its 20-day SMA, -12.72% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -21.61% and +38.02% respectively.
Stochastic %K and %D was 13.86% and 10.12% and the average true range (ATR) pointed at 0.0336. The RSI (14) points at 40.70%, while the 14-day stochastic is at 20.08% with the period’s ATR at 0.0354. The stock’s 9-day MACD Oscillator is pointing at -0.0154 and -0.0286 on the 14-day charts.
Analysts offering their rating for OGEN stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate OGEN as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is OGEN’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $2.25 and a high of $2.25, with their median price target at $2.25. Looking at these predictions, the average price target given by analysts is for Oragenics Inc. (OGEN) stock is $2.25.